Vitamin D deficiency in obese rats exacerbates nonalcoholic fatty liver disease and increases hepatic resistin and toll-like receptor activation

Hepatology

Volumn 55, Issue 4, 2012, Pages 1103-1111

  Roth, Christian L ^a   Elfers, Clinton T ^a   Figlewicz, Dianne P ^b,c   Melhorn, Susan J ^b   Morton, Gregory J ^c   Hoofnagle, Andrew ^c   Yeh, Matthew M ^c   Nelson, James E ^d   Kowdley, Kris V ^c,d,e  

^a SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^b VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d BENAROYA RESEARCH INSTITUTE   (United States)

^e VIRGINIA MASON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEME OXYGENASE 1; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; MESSENGER RNA; RESISTIN; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9; VITAMIN D;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE EXACERBATION; ENZYME ACTIVATION; GENE EXPRESSION; LIPID DIET; LIVER HISTOLOGY; LOW FAT DIET; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; VITAMIN D DEFICIENCY;

ANIMALS; COMORBIDITY; DIETARY CARBOHYDRATES; DIETARY FATS; DISEASE MODELS, ANIMAL; FATTY LIVER; INSULIN RESISTANCE; LIVER; MALE; OBESITY; OXIDATIVE STRESS; RATS; RATS, SPRAGUE-DAWLEY; RESISTIN; SEVERITY OF ILLNESS INDEX; TOLL-LIKE RECEPTORS; VITAMIN D DEFICIENCY;

EID: 84859164281     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.24737     Document Type: Article

References (46)

1. Sung KC, Kim SH. Interrelationship between fatty liver and insulin resistance in the development of type 2 diabetes. J Clin Endocrinol Metab 2011; 96: 1093-1097.
2. Schwimmer JB, Deutsch R, Kahen T, Lavine JE, Stanley C, Behling C. Prevalence of fatty liver in children and adolescents. Pediatrics 2006; 118: 1388-1393.
3. Kohli R, Boyd T, Lake K, Dietrich K, Nicholas L, Balistreri WF, et al. Rapid progression of NASH in childhood. J Pediatr Gastroenterol Nutr 2010; 50: 453-456.
4. Alvarez JA, Ashraf A. Role of vitamin D in insulin secretion and insulin sensitivity for glucose homeostasis. Int J Endocrinol 2010; 2010: 351385.
5. Smotkin-Tangorra M, Purushothaman R, Gupta A, Nejati G, Anhalt H, Ten S. Prevalence of vitamin D insufficiency in obese children and adolescents. J Pediatr Endocrinol Metab 2007; 20: 817-823.
6. Bradlee ML, Singer MR, Qureshi MM, Moore LL. Food group intake and central obesity among children and adolescents in the Third National Health and Nutrition Examination Survey (NHANES III). Public Health Nutr 2010; 13: 797-805.
7. Lenders CM, Feldman HA, Von Scheven E, Merewood A, Sweeney C, Wilson DM, et al. Relation of body fat indexes to vitamin D status and deficiency among obese adolescents. Am J Clin Nutr 2009; 90: 459-467.
8. Targher G, Bertolini L, Scala L, Cigolini M, Zenari L, Falezza G, et al. Associations between serum 25-hydroxyvitamin D3 concentrations and liver histology in patients with non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 2007; 17: 517-524.
9. Wu CC, Chang JH, Chen CC, Su SB, Yang LK, Ma WY, et al. Calcitriol treatment attenuates inflammation and oxidative stress in hemodialysis patients with secondary hyperparathyroidism. Tohoku J Exp Med 2011; 223: 153-159.
10. Manco M, Ciampalini P, Nobili V. Low levels of 25-hydroxyvitamin D(3) in children with biopsy-proven nonalcoholic fatty liver disease. HEPATOLOGY 2010; 51: 2229; author reply 2230.
11. Katz K, Brar PC, Parekh N, Liu YH, Weitzman M. Suspected nonalcoholic fatty liver disease is not associated with vitamin d status in adolescents after adjustment for obesity. J Obes 2010; 2010: 496829.
12. Raghuramulu N, Reddy V. Serum 25-hydroxy-vitamin D levels in malnourished children with rickets. Arch Dis Child 1980; 55: 285-287.
13. Fleet JC, Gliniak C, Zhang Z, Xue Y, Smith KB, McCreedy R, et al. Serum metabolite profiles and target tissue gene expression define the effect of cholecalciferol intake on calcium metabolism in rats and mice. J Nutr 2008; 138: 1114-1120.
14. Alemzadeh R, Kichler J, Babar G, Calhoun M. Hypovitaminosis D in obese children and adolescents: relationship with adiposity, insulin sensitivity, ethnicity, and season. Metabolism 2008; 57: 183-191.
15. Nelson JE, Wilson L, Brunt EM, Yeh MM, Kleiner DE, Unalp-Arida A, et al. Relationship between the pattern of hepatic iron deposition and histological severity in nonalcoholic fatty liver disease. HEPATOLOGY 2011; 53: 448-457.
16. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. HEPATOLOGY 2005; 41: 1313-1321.
17. German JP, Wisse BE, Thaler JP, Oh-I S, Sarruf DA, Ogimoto K, et al. Leptin deficiency causes insulin resistance induced by uncontrolled diabetes. Diabetes 2010; 59: 1626-1634.
18. Hoofnagle AN, Laha TJ, Donaldson TF. A rubber transfer gasket to improve the throughput of liquid-liquid extraction in 96-well plates: application to vitamin D testing. J Chromatogr B Analyt Technol Biomed Life Sci 2010; 878: 1639-1642.
19. Nakano T, Cheng YF, Lai CY, Hsu LW, Chang YC, Deng JY, et al. Impact of artificial sunlight therapy on the progress of non-alcoholic fatty liver disease in rats. J Hepatol 2010; 55: 415-425.
20. Roth CL, Blevins JE, Ralston M, Elfers C, Ogimoto K, Kaiyala KJ, et al. A novel rodent model that mimics the metabolic sequelae of obese craniopharyngioma patients. Pediatr Res 2011; 69: 230-236.
21. Gaemers IC, Stallen JM, Kunne C, Wallner C, van Werven J, Nederveen A, et al. Lipotoxicity and steatohepatitis in an overfed mouse model for non-alcoholic fatty liver disease. Biochim Biophys Acta 2011; 1812: 447-458.
22. Wortham M, He L, Gyamfi M, Copple BL, Wan YJ. The transition from fatty liver to NASH associates with SAMe depletion in db/db mice fed a methionine choline-deficient diet. Dig Dis Sci 2008; 53: 2761-2774.
23. Zelber-Sagi S, Nitzan-Kaluski D, Goldsmith R, Webb M, Blendis L, Halpern Z, et al. Long term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD): a population based study. J Hepatol 2007; 47: 711-717.
24. Tirelli E, Laviola G, Adriani W. Ontogenesis of behavioral sensitization and conditioned place preference induced by psychostimulants in laboratory rodents. Neurosci Biobehav Rev 2003; 27: 163-178.
25. Fracanzani AL, Valenti L, Bugianesi E, Andreoletti M, Colli A, Vanni E, et al. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. HEPATOLOGY 2008; 48: 792-798.
26. Choudhury J, Sanyal AJ. Insulin resistance and the pathogenesis of nonalcoholic fatty liver disease. Clin Liver Dis 2004; 8: 575-594, ix.
27. Chiu KC, Chu A, Go VL, Saad MF. Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. Am J Clin Nutr 2004; 79: 820-825.
28. Tilg H. Obesity, metabolic syndrome, and microbiota: multiple interactions. J Clin Gastroenterol 2010; 44(Suppl 1): S16-S18.
29. Kanuri G, Spruss A, Wagnerberger S, Bischoff SC, Bergheim I. Role of tumor necrosis factor α (TNFα) in the onset of fructose-induced nonalcoholic fatty liver disease in mice. J Nutr Biochem 2011; 22: 527-534.
30. Giulietti A, van Etten E, Overbergh L, Stoffels K, Bouillon R, Mathieu C. Monocytes from type 2 diabetic patients have a pro-inflammatory profile. 1, 25-Dihydroxyvitamin D(3) works as anti-inflammatory. Diabetes Res Clin Pract 2007; 77: 47-57.
31. Zarrabeitia MT, Riancho JA, Amado JA, Olmos JM, Gonzalez-Macias J. Effect of calcitriol on the secretion of prostaglandin E2, interleukin 1, and tumor necrosis factor alpha by human monocytes. Bone 1992; 13: 185-189.
32. Khoo AL, Chai LY, Koenen HJ, Sweep FC, Joosten I, Netea MG, et al. Regulation of cytokine responses by seasonality of vitamin D status in healthy individuals. Clin Exp Immunol 2011; 164: 72-79.
33. Miura K, Seki E, Ohnishi H, Brenner DA. Role of Toll-like receptors and their downstream molecules in the development of nonalcoholic Fatty liver disease. Gastroenterol Res Pract 2010; 2010: 362847.
34. Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 2011; 34: 637-650.
35. Lorenz E. TLR2 and TLR4 expression during bacterial infections. Curr Pharm Des 2006; 12: 4185-4193.
36. Horng T, Barton GM, Flavell RA, Medzhitov R. The adaptor molecule TIRAP provides signalling specificity for Toll-like receptors. Nature 2002; 420: 329-333.
37. Toshimitsu K, Matsuura B, Ohkubo I, Niiya T, Furukawa S, Hiasa Y, al. Dietary habits and nutrient intake in non-alcoholic steatohepatitis. Nutrition 2007; 23: 46-52.
38. Dickie LJ, Church LD, Coulthard LR, Mathews RJ, Emery P, McDermott MF. Vitamin D3 down-regulates intracellular Toll-like receptor 9 expression and Toll-like receptor 9-induced IL-6 production in human monocytes. Rheumatology (Oxford) 2010; 49: 1466-1471.
39. Bjorbaek C, El-Haschimi K, Frantz JD, Flier JS. The role of SOCS-3 in leptin signaling and leptin resistance. J Biol Chem 1999; 274: 30059-30065.
40. Frobose H, Ronn SG, Heding PE, Mendoza H, Cohen P, Mandrup-Poulsen T, et al. Suppressor of cytokine Signaling-3 inhibits interleukin-1 signaling by targeting the TRAF-6/TAK1 complex. Mol Endocrinol 2006; 20: 1587-1596.
41. Vidal-Puig A, O'Rahilly S. Resistin: a new link between obesity and insulin resistance? Clin Endocrinol (Oxf) 2001; 55: 437-438.
42. Szalowska E, Elferink MG, Hoek A, Groothuis GM, Vonk RJ. Resistin is more abundant in liver than adipose tissue and is not up-regulated by lipopolysaccharide. J Clin Endocrinol Metab 2009; 94: 3051-3057.
43. Zhang J, Lei T, Chen X, Peng Y, Long H, Zhou L, et al. Resistin up-regulates COX-2 expression via TAK1-IKK-NF-kappaB signaling pathway. Inflammation 2010; 33: 25-33.
44. Arkan MC, Hevener AL, Greten FR, Maeda S, Li ZW, Long JM, et al. IKK-beta links inflammation to obesity-induced insulin resistance. Nat Med 2005; 11: 191-198.
45. Kathirvel E, Chen P, Morgan K, French SW, Morgan TR. Oxidative stress and regulation of anti-oxidant enzymes in cytochrome P4502E1 transgenic mouse model of non-alcoholic fatty liver. J Gastroenterol Hepatol 2010; 25: 1136-1143.
46. Gomez-Hurtado I, Zapater P, Bellot P, Pascual S, Pérez-Mateo M, Such J, et al. Interleukin-10-mediated heme oxygenase 1-induced underlying mechanism in inflammatory down-regulation by norfloxacin in cirrhosis. HEPATOLOGY 2011; 53: 935-944.